RYEQO 40 mg/1 mg/0.5 mg, film-coated tablets 28 tablets
Active ingredients: (17R)-norethindrone acetate, 17β-estradiol, Estradiol hemihydrate, Relugolix
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet28 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- RYEQO 40 mg/1 mg/0,5 mg, comprimés pelliculés
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquettes thermoformée(s) PVC aluminium de 28 comprimés
- Marketing authorisation holder
- GEDEON RICHTER ( HONGRIE)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 20 Jan 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
64049405CIP73029165CIP133400930291658Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ESTRADIOLcomprimé | 1 mg · un comprimé | FT |
| ACÉTATE DE NORÉTHISTÉRONEcomprimé | 0,5 mg · un comprimé | SA |
| RÉLUGOLIXcomprimé | 40 mg · un comprimé | SA |
| ESTRADIOL HÉMIHYDRATÉcomprimé | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.